Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Overview
A randomised, multi-centre, intra-patient imaging and dosimetry crossover study of lutetium (177Lu) rhPSMA 10.1 and lutetium (177Lu) vipivotide tetraxetan (Pluvicto®) in patients with non-curative metastatic prostate cancer
Sponsor
Blue Earth Therapeutics, LTDPhase
Early Phase 1
Contacts
Blue Earth Therapeutics
contact@blueearthtx.com
+44 (0)1865634500
ClinicalTrials.gov
NCT06516510Patient Education
Patient education not yet provided.
Publications
Publications not yet provided.
Locations
Loading…
Help us improve your experience